Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling
Cancer Science · 2023
DOI: 10.1111/cas.15948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Weixi Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, MicroRNAs, Exosomes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Medical and Health Science and Technology Project.
Abstract (Originalsprache)
Despite the clinical benefits of androgen deprivation therapy, most patients with advanced androgen‐dependent prostate cancer (ADPC) eventually relapse and progress to lethal androgen‐independent prostate cancer (AIPC), also termed castration‐resistant prostate cancer (CRPC). MiRNAs can be packaged into exosomes (Exos) and shuttled between cells. However, the roles and mechanisms of exosomal miRNAs involved in CRPC progression have not yet been fully elucidated. Here, we find that miR‐222‐3p is elevated in AIPC cells, which results in remarkable enhancement of cell proliferation, migration, and invasion ability. Furthermore, Exos released by AIPC cells can be uptaken by ADPC cells, thus acclimating ADPC cells to progressing to more aggressive cell types in vitro and in vivo through exosomal transfer of miR‐222‐3p. Mechanistically, Exos‐miR‐222‐3p promoted ADPC cells transformed to AIPC‐like cells, at least in part, by activating mTOR signaling through targeting MIDN. Our results show that AIPC cells secrete Exos containing miRNA cargo. These cargos can be transferred to ADPC cells through paracrine mechanisms that have a strong impact on cellular functional remodeling. The current work underscores the great therapeutic potential of targeting Exo miRNAs, either as a single agent or combined with androgen receptor pathway inhibitors for CRPC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China.
- Department of Blood Transfusion, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China.
- Department of Laboratory Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
ORCID-Profile: Zhihua Tao, Weiwei Liu
Förderung
- National Natural Science Foundation of China
- Zhejiang Medical and Health Science and Technology Project
Zitieren
APA
Wang, W., Kong, P., Feng, K., Liu, C., Gong, X., Sun, T., Duan, X., Sang, Y., Jiang, Y., Li, X., Zhang, L., Tao, Z., & Liu, W. (2023). Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling. Cancer Science. https://doi.org/10.1111/cas.15948
Vancouver
Wang W, Kong P, Feng K, Liu C, Gong X, Sun T, et al. Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling. Cancer Science. 2023. doi:10.1111/cas.15948
BibTeX
@article{Wang2023,
author = {Wang, Weixi and Kong, Piaoping and Feng, Kangle and Liu, Chunhua and Gong, Xubo and Sun, Tao and Duan, Xiuzhi and Sang, Yiwen and Jiang, Yu and Li, Xiang and Zhang, Lingyu and Tao, Zhihua and Liu, Weiwei},
title = {Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15948}
}
EUVIMED